tebu-bio, today announced its first ADME seminar in Paris to celebrate 10 years serving the ADME community. (October 9th, 2008; Maison de la Chimie, France).
This seminar, “From in vitro ADME studies to pharmacokinetics prediction”, aims to provide European experts with an overview of the latest technologies in the ADME-Tox and early-ADME fields. Scientists will get an accurate picture of ADME-Tox properties, drug-drug interactions, transporters assessment and pharmacokinetics prediction.
The participants will have the opportunity to discuss their upcoming projects and research programs with tebu-bio product specialists and leading world-wide manufacturers (Advancell, Cypex, Noray Bio, Solvo Biotechnology, Xenotech, tebu-bio laboratories)
“We wanted to develop the European ADME-Tox network by creating a forum where experts in the ADME-Tox enviroment can discuss the latest advances in their field.” said Donald van Dijk, CEO of tebu-bio.
“It’s a fantastic opportunity to thank our ADME customers who have worked with us for the last 10 years, since tebu-bio became the first company to introduce cryopreserved hepatocytes in Europe” added Dr Lecommandeur, VP Business Development Manager.
This seminar will take place in the historic French conference centre “La Maison de la Chimie” in Paris (room 201; October 9th, 2008).
Seminar programme, registration form, and accommodation details are available online at http://adme.tebu-
